385 related articles for article (PubMed ID: 25445929)
1. Indacaterol and tiotropium combination therapy in patients with chronic obstructive pulmonary disease.
Matsushima S; Inui N; Yasui H; Kono M; Nakamura Y; Toyoshima M; Shirai T; Suda T
Pulm Pharmacol Ther; 2015 Feb; 30():11-5. PubMed ID: 25445929
[TBL] [Abstract][Full Text] [Related]
2. Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease.
Inui N; Matsushima S; Kato S; Yasui H; Kono M; Fujisawa T; Enomoto N; Nakamura Y; Toyoshima M; Suda T
Int J Chron Obstruct Pulmon Dis; 2015; 10():1139-46. PubMed ID: 26124653
[TBL] [Abstract][Full Text] [Related]
3. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
[TBL] [Abstract][Full Text] [Related]
4. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.
Mahler DA; D'Urzo A; Bateman ED; Ozkan SA; White T; Peckitt C; Lassen C; Kramer B;
Thorax; 2012 Sep; 67(9):781-8. PubMed ID: 22544891
[TBL] [Abstract][Full Text] [Related]
5. Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients.
Hoshino M; Ohtawa J
Respirology; 2014 Apr; 19(3):403-10. PubMed ID: 24708031
[TBL] [Abstract][Full Text] [Related]
6. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease.
Hoshino M; Ohtawa J; Akitsu K
Pulm Pharmacol Ther; 2015 Feb; 30():128-33. PubMed ID: 25183687
[TBL] [Abstract][Full Text] [Related]
7. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.
Mahler DA; Buhl R; Lawrence D; McBryan D
Pulm Pharmacol Ther; 2013 Jun; 26(3):348-55. PubMed ID: 23434446
[TBL] [Abstract][Full Text] [Related]
10. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.
Rossi A; Centanni S; Cerveri I; Gulotta C; Foresi A; Cazzola M; Brusasco V
Respir Med; 2012 Jan; 106(1):84-90. PubMed ID: 22035851
[TBL] [Abstract][Full Text] [Related]
11. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
[TBL] [Abstract][Full Text] [Related]
12. Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients.
Mroz RM; Minarowski L; Chyczewska E
Adv Exp Med Biol; 2013; 756():23-8. PubMed ID: 22836615
[TBL] [Abstract][Full Text] [Related]
13. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.
Buhl R; Dunn LJ; Disdier C; Lassen C; Amos C; Henley M; Kramer B;
Eur Respir J; 2011 Oct; 38(4):797-803. PubMed ID: 21622587
[TBL] [Abstract][Full Text] [Related]
14. Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease.
Nishijima Y; Minami S; Yamamoto S; Ogata Y; Koba T; Futami S; Komuta K
Int J Chron Obstruct Pulmon Dis; 2015; 10():439-44. PubMed ID: 25767381
[TBL] [Abstract][Full Text] [Related]
15. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
Rennard S; Bantje T; Centanni S; Chanez P; Chuchalin A; D'Urzo A; Kornmann O; Perry S; Jack D; Owen R; Higgins M
Respir Med; 2008 Jul; 102(7):1033-44. PubMed ID: 18479895
[TBL] [Abstract][Full Text] [Related]
16. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
Donohue JF; Fogarty C; Lötvall J; Mahler DA; Worth H; Yorgancioglu A; Iqbal A; Swales J; Owen R; Higgins M; Kramer B;
Am J Respir Crit Care Med; 2010 Jul; 182(2):155-62. PubMed ID: 20463178
[TBL] [Abstract][Full Text] [Related]
17. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
Beeh KM; Korn S; Beier J; Jadayel D; Henley M; D'Andrea P; Banerji D
Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204
[TBL] [Abstract][Full Text] [Related]
18. The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.
Kerstjens HA; Deslée G; Dahl R; Donohue JF; Young D; Lawrence D; Kornmann O
Pulm Pharmacol Ther; 2015 Jun; 32():101-8. PubMed ID: 25743376
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study.
Fujimoto K; Yamazaki H; Ura M; Kitaguchi Y
Int J Chron Obstruct Pulmon Dis; 2017; 12():3195-3201. PubMed ID: 29138547
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences.
Ohno T; Wada S; Hanada S; Sawaguchi H; Muraki M; Tohda Y
Int J Chron Obstruct Pulmon Dis; 2014; 9():107-14. PubMed ID: 24489464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]